Samrat Pharmachem [SAMRATPH] vs Gujarat Alkalies [GUJALKALI] Detailed Stock Comparison

Samrat Pharmachem

BSE
Loading...

Gujarat Alkalies

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Samrat Pharmachem wins in 9 metrics, Gujarat Alkalies wins in 10 metrics, with 0 ties. Gujarat Alkalies appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricSamrat PharmachemGujarat AlkaliesBetter
P/E Ratio (TTM)20.0070.12Samrat Pharmachem
Price-to-Book Ratio1.340.68Gujarat Alkalies
Debt-to-Equity Ratio13.819.30Gujarat Alkalies
PEG Ratio-0.18-1.02Gujarat Alkalies
EV/EBITDA13.6111.23Gujarat Alkalies
Profit Margin (TTM)1.72%-0.82%Samrat Pharmachem
Operating Margin (TTM)-0.06%1.34%Gujarat Alkalies
EBITDA Margin (TTM)N/A1.34%N/A
Return on Equity9.91%-1.15%Samrat Pharmachem
Return on Assets (TTM)5.85%-0.82%Samrat Pharmachem
Free Cash Flow (TTM)$-105.99M$557.34MGujarat Alkalies
Dividend Yield0.29%4.82%Gujarat Alkalies
1-Year Return-44.72%-35.85%Gujarat Alkalies
Price-to-Sales Ratio (TTM)0.340.97Samrat Pharmachem
Enterprise Value$1.06B$45.24BGujarat Alkalies
EV/Revenue Ratio0.381.08Samrat Pharmachem
Gross Profit Margin (TTM)2.99%60.26%Gujarat Alkalies
Revenue per Share (TTM)$908$573Samrat Pharmachem
Earnings per Share (Diluted)$15.59$-4.72Samrat Pharmachem
Beta (Stock Volatility)-0.40-0.38Samrat Pharmachem
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Samrat Pharmachem vs Gujarat Alkalies Stock Performance Analysis

Loading Price Chart...

Samrat Pharmachem
Gujarat Alkalies
Samrat Pharmachem Stock Overview | Gujarat Alkalies Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Samrat Pharmachem-1.52%3.37%-4.23%-18.68%-2.82%-21.57%
Gujarat Alkalies-0.02%3.23%-5.46%-2.36%-6.65%-24.87%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Samrat Pharmachem-44.72%-69.64%176.70%598.52%1,337.94%1,818.75%
Gujarat Alkalies-35.85%-36.55%78.76%234.03%329.61%296.96%

News Based Sentiment: Samrat Pharmachem vs Gujarat Alkalies

Samrat Pharmachem

News based Sentiment: MIXED

October was a month of contrasting fortunes for Samrat Pharmachem, with a significant initial stock surge quickly followed by a decline to a 52-week low. This volatility, combined with mixed financial results, creates a complex investment picture that requires careful consideration.

View Samrat Pharmachem News Sentiment Analysis

Gujarat Alkalies

News based Sentiment: MIXED

The month featured a significant earnings turnaround for Gujarat Alkalies, but this was coupled with conflicting analyst signals and recent stock performance declines. While the Q1 results are positive, the mixed sentiment creates uncertainty for investors, making this a moderately important month for the company's investment story.

View Gujarat Alkalies News Sentiment Analysis

Performance & Financial Health Analysis: Samrat Pharmachem vs Gujarat Alkalies

MetricSAMRATPHGUJALKALI
Market Information
Market Cap i₹1.03B₹41.82B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i1,85037,677
90 Day Avg. Volume i1,30650,754
Last Close₹307.00₹561.50
52 Week Range₹289.00 - ₹425.00₹483.60 - ₹900.00
% from 52W High-27.76%-37.61%
All-Time High₹1,250.00 (Sep 19, 2022)₹1,044.70 (May 02, 2022)
% from All-Time High-75.44%-46.25%
Growth Metrics
Quarterly Revenue Growth-0.06%0.13%
Quarterly Earnings Growth-0.06%0.13%
Financial Health
Profit Margin (TTM) i0.02%-0.01%
Operating Margin (TTM) i0.00%0.01%
Return on Equity (TTM) i0.10%-0.01%
Debt to Equity (MRQ) i13.819.30
Cash & Liquidity
Book Value per Share (MRQ)₹232.02₹819.92
Cash per Share (MRQ)₹1.70₹20.86
Operating Cash Flow (TTM) i₹1.26M₹-2,688,119,000
Levered Free Cash Flow (TTM) i₹71.12M₹-651,186,000
Dividends
Last 12-Month Dividend Yield i0.29%4.82%
Last 12-Month Dividend i₹1.00₹29.65

Valuation & Enterprise Metrics Analysis: Samrat Pharmachem vs Gujarat Alkalies

MetricSAMRATPHGUJALKALI
Price Ratios
P/E Ratio (TTM) i20.0070.12
Forward P/E iN/A6.43
PEG Ratio i-0.18-1.02
Price to Sales (TTM) i0.340.97
Price to Book (MRQ) i1.340.68
Market Capitalization
Market Capitalization i₹1.03B₹41.82B
Enterprise Value i₹1.06B₹45.24B
Enterprise Value Metrics
Enterprise to Revenue i0.381.08
Enterprise to EBITDA i13.6111.23
Risk & Other Metrics
Beta i-0.40-0.38
Book Value per Share (MRQ) i₹232.02₹819.92

Financial Statements Comparison: Samrat Pharmachem vs Gujarat Alkalies

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)SAMRATPHGUJALKALI
Revenue/Sales i₹756.52M₹11.05B
Cost of Goods Sold i₹733.90M₹4.39B
Gross Profit i₹22.62M₹6.66B
Research & Development iN/AN/A
Operating Income (EBIT) i₹-456,000₹147.50M
EBITDA i₹8.16M₹1.04B
Pre-Tax Income i₹2.08M₹-120.20M
Income Tax i₹4.37M₹17.60M
Net Income (Profit) i₹-2.29M₹-137.80M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)SAMRATPHGUJALKALI
Cash & Equivalents i₹483,000₹1.26B
Total Current Assets i₹1.03B₹10.55B
Total Current Liabilities i₹495.83M₹9.33B
Long-Term Debt i₹0₹5.35B
Total Shareholders Equity i₹718.00M₹56.70B
Retained Earnings i₹687.11M₹16.56B
Property, Plant & Equipment i₹0₹2.20B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)SAMRATPHGUJALKALI
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricSAMRATPHGUJALKALI
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i1,85037,677
Average Daily Volume (90 Day) i1,30650,754
Shares Outstanding i3.09M73.44M
Float Shares i1.26M17.12M
% Held by Insiders i0.59%0.78%
% Held by Institutions i0.00%0.04%

Dividend Analysis & Yield Comparison: Samrat Pharmachem vs Gujarat Alkalies

MetricSAMRATPHGUJALKALI
Last 12-Month Dividend i₹1.00₹29.65
Last 12-Month Dividend Yield i0.29%4.82%
3-Year Avg Annual Dividend i₹1.67₹21.07
3-Year Avg Dividend Yield i0.17%2.19%
3-Year Total Dividends i₹5.00₹63.20
Ex-Dividend DateSep 19, 2024Sep 19, 2025